In addition, oral BTK inhibitors administered alone 4, or combinations of ibrutinib with rituximab 5, or ibrutinib with the Bcl2-antagonist venetoclax 6,7, have proven as interesting chemotherapy-free targeted therapeutic approaches for MCL patients at relapse 8. Here, BCL2 is linked to mantle cell lymphoma.